Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels.
Amanda J NicollStuart Keith RobertsRicky LimJoanne MitchellMartin WeltmanJacob GeorgeAlan WiggKatherine StuartPaul GowGerry MacQuillanEdmund TseMiriam LevySiddharth SoodAmany ZekryWendy ChengJonathan MitchellRichard SkoienWilliam SievertSimone I StrasserGeoffrey W McCaughannull nullPublished in: Alimentary pharmacology & therapeutics (2019)
Mycophenolate remains an excellent treatment option for patients with AIH refractory to or intolerant of standard therapy with those most likely to benefit being older and/or having lower pre-treatment IgG levels.